Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

From OmniJournal
Revision as of 14:47, 24 July 2020 by Jtodaro2 (talk | contribs) (Created page with "{| class="infobox" width=200px |style="width:100%; font-size:24px;"|'''Publication''' |- |Title || <ul>[https://www.nejm.org/doi/full/10.1056/NEJMoa2019014 Hydroxychloroquine...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Publication
Title
Authors
  • Alexandre Cavalcanti
  • Fernando Zampieri
  • Regis Rosa
  • ...
  • Otavio Berwanger
Journal NEJM
Date July 23, 2020

A randomized, open-label controlled trial of 504 patients with mild-to-moderate COVID-19 were treated with standard care, hydroxychloroquine or hydroxychloroquine plus azithromycin resulted in no difference in clinical status at 15 days.

Major Issues

Contribute here!

Minor Issues

Contribute here!

Impact

Contribute here!

Article Revisions

No revisions reported at this time.

References